TapImmune Inc Share Price Nasdaq
Stocks
US8760334081
Biotechnology & Medical Research
| Market Cap | 18.34M 16.19M 15.31M 13.89M 26.04M 1.76B 26.29M 184M 70.8M 899M 68.87M 67.37M 2.89B | P/E 2026 * |
-1.85x | P/E 2027 * | -1.25x |
|---|---|---|---|---|---|
| Enterprise Value | 18.34M 16.19M 15.31M 13.89M 26.04M 1.76B 26.29M 184M 70.8M 899M 68.87M 67.37M 2.89B | EV / Sales 2026 * |
4.32x | EV / Sales 2027 * | 0.91x |
| Free-Float |
94.51% | Yield 2026 * |
-
| Yield 2027 * | - |
| 20/08/21 | Wall Street hoger gesloten | |
| 20/08/21 | Wall Street koerst af op hoger slot | |
| 20/08/21 | Wall Street richting lagere opening |
| 1 day | +4.17% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juan Vera
CEO | Chief Executive Officer | 46 | 30/04/2023 |
| Chief Operating Officer | 36 | 30/11/2023 | |
Patricia Allison
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Juan Vera
BRD | Director/Board Member | 46 | 16/10/2018 |
Norman Eansor
CHM | Chairman | 65 | 23/05/2022 |
Steven Elms
BRD | Director/Board Member | 62 | 05/08/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.17% | -12.24% | - | - | 18.76M | |
| -0.03% | +3.77% | +12.35% | +37.22% | 49.06B | |
| -0.73% | -0.41% | +48.84% | +36.72% | 44.6B | |
| +1.36% | +6.03% | +343.85% | +638.73% | 43.24B | |
| -0.47% | -0.76% | +9.75% | +103.07% | 41.73B | |
| +0.34% | +0.22% | +5.18% | +47.36% | 29.93B | |
| +1.00% | -1.28% | +24.23% | +156.93% | 17.19B | |
| -3.20% | -3.50% | +25.33% | +42.43% | 15.54B | |
| -2.94% | +6.98% | +5.10% | - | 15.35B | |
| -0.86% | -4.00% | - | - | 15.11B | |
| Average | -0.14% | +1.13% | +59.33% | +151.78% | 30.19B | |
| Weighted average by Cap. | -0.28% | +1.79% | +74.43% | +166.43% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.24M 3.74M 3.54M 3.21M 6.02M 407M 6.08M 42.49M 16.38M 208M 15.93M 15.58M 669M | 20.19M 17.81M 16.85M 15.29M 28.66M 1.94B 28.94M 202M 77.93M 989M 75.8M 74.15M 3.18B |
| Net income | -11.84M -10.45M -9.88M -8.96M -16.8M -1.14B -16.97M -119M -45.69M -580M -44.45M -43.48M -1.87B | -18.09M -15.97M -15.11M -13.7M -25.68M -1.74B -25.94M -181M -69.84M -886M -67.93M -66.46M -2.85B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
